• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer to create separate internal, global innovative and value businesses

Pfizer to create separate internal, global innovative and value businesses

July 29, 2013
CenterWatch Staff

Pfizer has announced plans to internally separate its commercial operations into three business segments, two of which will include innovative business lines and a third to include the value business line. 

Each of the three segments will include both developed and emerging markets. The changes will be implemented in January 2014 in countries that do not require a consultation with works councils or unions, and in countries that require consultation after the successful conclusion of those processes. Beginning with the first-quarter 2014 financial results, the company will provide financial transparency for each of these three business segments, which will include a 2014 baseline management view of profit and loss for each segment. 

One of the innovative business segments will be led by Geno Germano, group president, innovative products group. It will include products across multiple therapeutic areas  expected to have market exclusivity beyond 2015, including inflammation and immunology, CV/metabolic, neuroscience and pain, rare diseases and women's/men's health.

The other innovative business segment will include vaccines, oncology and consumer healthcare and will be led by Amy Schulman, group president, vaccines, oncology and consumer healthcare. Each of these businesses will operate as a separate global business and require distinct specialization in terms of the science, talent and market approach required to deliver value to consumers and patients.

The value business segment will be led by John Young, group president, value products group, and will include products that generate strong, consistent cash flow and will be positioned to provide patients access to effective, lower-cost, high-value treatments.  In addition to products that have lost market exclusivity, it will generally include mature, patent-protected products expected to lose exclusivity through 2015 in most major markets, biosimilars and current and future established product collaborations, such as Pfizer’s existing partnerships with Mylan in Japan, Teuto in Brazil and Hisun in China.

Olivier Brandicourt will lead the transition from the current emerging markets organization to the regional structure that will be established for each of the three business segments.     

In connection with the changes, Douglas Lankler, currently chief compliance and risk officer, will become general counsel, and Rady Johnson, currently senior vice president and associate general counsel, will become chief compliance and risk officer.   

"This represents the next steps in Pfizer's journey to further revitalize our innovative core, enhance the value of our consumer and off-patent established brands and maximize the use of our capital to create value for Pfizer and our shareholders,” said Ian Read, chairman and chief executive officer. “Through this evolution, we will enable greater independence and focus for the innovative and value businesses. Our new commercial operating model will provide each business with an enhanced ability to respond to market dynamics, greater visibility and focus and distinctive capabilities optimized to deliver value to patients and shareholders in the coming years."

All leadership changes will be effective Jan. 1, 2014.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing